Immatics spikes on a round of promising — but still early — autologous cell therapy data for solid tumors

Coming off some recent setbacks, Immatics is rolling out its latest update on a new approach to solid tumors that’s bolstered hopes and inspired a …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Im­mat­ics spikes on a round of promis­ing — but still ear­ly — au­tol­o­gous cell ther­a­py da­ta for sol­id tu­mors